Morral Merce, Güell José L, El Husseiny Mostafa A, Elies Daniel, Gris Oscar, Manero Felicidad
From Instituto de Microcirugia Ocular (Morral, Güell, Elies, Gris, Manero) and Universitat Autonoma de Barcelona (Güell), Barcelona, Spain; European School for Advanced Studies in Ophthalmology (Güell), Lugano, Switzerland; Cornea and Refractive Surgery Department (El Husseiny), Research Institute of Ophthalmology, Giza, Egypt.
From Instituto de Microcirugia Ocular (Morral, Güell, Elies, Gris, Manero) and Universitat Autonoma de Barcelona (Güell), Barcelona, Spain; European School for Advanced Studies in Ophthalmology (Güell), Lugano, Switzerland; Cornea and Refractive Surgery Department (El Husseiny), Research Institute of Ophthalmology, Giza, Egypt.
J Cataract Refract Surg. 2016 Jan;42(1):117-26. doi: 10.1016/j.jcrs.2015.08.018.
To compare the corneal endothelial cell density (ECD) after unilateral iris-claw phakic intraocular lens (pIOL) implantation.
Instituto de Microcirugia Ocular, Barcelona, Spain.
Retrospective interventional nonrandomized paired-eye comparison.
Patients who had pIOL implantation in 1 eye and corneal refractive surgery (Group 1) or no surgery in the fellow eye (Group 2) between 1998 and 2010 were included. The main outcome measures were central corneal ECD and the percentage of corneal endothelial cell loss. Secondary outcome measures were uncorrected distance visual acuity, corrected distance visual acuity, manifest refraction, and complications. Outcome measures were analyzed 1, 5, and 10 years postoperatively.
Both groups comprised 29 patients. Ten years after surgery, the mean endothelial cell loss was 6.41% ± 8.02% (SD) (Group 1, iris-claw pIOLs), 5.59% ± 5.98% (Group 1, corneal refractive surgery), 7.84% ± 6.83% (Group 2, iris-claw pIOLs), and 6.74% ± 3.97% (Group 2, no surgery). No significant endothelial cell loss was observed after pIOL implantation or corneal refractive surgery at any timepoint (P > .05). No significant differences were observed in the percentage of endothelial cell loss between the groups (P > .05).
Iris-claw pIOL implantation did not produce significant corneal endothelial cell loss up to 10 years after surgery compared with corneal refractive surgery and unoperated eyes when strict inclusion criteria were met.
Dr. Güell is a consultant to Ophtec BV and Carl Zeiss Meditec AG. No other author has a financial or proprietary interest in any material or method mentioned.
比较单侧虹膜爪型有晶状体眼人工晶状体(pIOL)植入术后的角膜内皮细胞密度(ECD)。
西班牙巴塞罗那眼显微外科研究所。
回顾性干预性非随机配对眼比较。
纳入1998年至2010年间一只眼植入pIOL且另一只眼进行角膜屈光手术(第1组)或未进行手术(第2组)的患者。主要观察指标为中央角膜ECD和角膜内皮细胞丢失百分比。次要观察指标为未矫正远视力、矫正远视力、明显屈光不正和并发症。术后1年、5年和10年对观察指标进行分析。
两组均有29例患者。术后10年,平均内皮细胞丢失率分别为6.41%±8.02%(标准差)(第1组,虹膜爪型pIOL)、5.59%±5.98%(第1组,角膜屈光手术)、7.84%±6.83%(第2组,虹膜爪型pIOL)和6.74%±3.97%(第2组,未手术)。在任何时间点,pIOL植入或角膜屈光手术后均未观察到明显的内皮细胞丢失(P>.05)。两组之间内皮细胞丢失百分比无显著差异(P>.05)。
当满足严格的纳入标准时,与角膜屈光手术和未手术眼相比,虹膜爪型pIOL植入术后10年内未产生明显的角膜内皮细胞丢失。
Güell博士是Ophtec BV和卡尔蔡司医疗技术股份公司的顾问。其他作者对文中提及的任何材料或方法均无财务或专利权益。